Health
Ozempic-style drugs linked to major slowdown in cancer spread, new study finds
NEWYou can now listen to Fox News articles!
Popular glucagon-like peptide-1 (GLP-1) weight-loss drugs may help slow the spread of some cancers, according to new research to be presented at a major medical conference.
Research led by Cleveland Clinic found that the medications may reduce the spread of several obesity-related cancers, including lung, breast, colorectal and liver cancers.
The findings will be presented at the 2026 ASCO Annual Meeting next week in Chicago.
WEIGHT-LOSS DRUGS NOW LINKED TO CANCER PROTECTION IN WOMEN, MAJOR NEW STUDY REVEALS
According to a press release, the real-world retrospective study included 12,112 patients with the following types of obesity-related cancers, ranging from stage 1 to stage 3.
Popular GLP-1 weight-loss drugs may help slow the spread of some cancers, according to new research to be presented at a major medical conference. (iStock)
- Breast adenocarcinoma
- Prostate adenocarcinoma
- Non-small cell lung cancer (NSCLC)
- Colorectal adenocarcinoma
- Hepatocellular carcinoma (liver cancer)
- Renal cell carcinoma
- Pancreatic adenocarcinoma
Half of the participants started a GLP-1 medication – semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide or pramlintide – after their cancer diagnosis.
The other half began taking a DPP-4 inhibitor comparator “gliptins,” a different class of diabetes medications, the study noted.
WEIGHT-LOSS DRUGS’ IMPACT ON CANCER RISK REVEALED IN NEW STUDY
Compared to the patients taking gliptins, the GLP-1 users were found to have significantly lower progression to stage 4 disease for four types of cancers.
The biggest risk reduction was for non-small cell lung cancer (50%), followed by breast cancer (43%), colorectal cancer (31%) and liver cancer (38%).
Compared to the patients taking gliptins, the GLP-1 users were found to have significantly lower progression to stage 4 disease for four types of cancers. (iStock)
“Our study found that use of GLP-1 drugs, compared to DPP-4 inhibitors and other antidiabetic drugs, was associated with a meaningful reduction in cancer progression across four solid tumor types,” said lead study author Mark David Orland, MD, of the Taussig Cancer Institute at Cleveland Clinic, in the release. “It provides early evidence that future studies are worth pursuing.”
CLICK HERE FOR MORE HEALTH STORIES
Three other types of cancer – prostate, pancreatic and kidney – also had lower rates of spread among those taking GLP-1s, but those differences were “not statistically significant,” the researchers noted.
“Our study found that use of GLP-1 drugs … was associated with a meaningful reduction in cancer progression across four solid tumor types.”
Tumors with higher levels of GLP-1 receptors — proteins that help cells respond to GLP-1 hormones and drugs — were also linked to better survival outcomes, according to the study findings.
Overall, patients whose tumors had more of these receptors were about one-third less likely to die during the study period.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The incidence of adverse side effects was similar between GLP-1 and gliptin groups.
The findings suggest that GLP-1 pathways may directly influence how some cancers grow or spread, though researchers say more studies are needed to understand the mechanism behind this effect.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The study, which has not yet been peer-reviewed, had some limitations, according to the researchers. As it was retrospective and observational in design – as opposed to a randomized clinical trial – it couldn’t prove that GLP-1 drugs directly prevent cancer progression.
The findings suggest that GLP-1 pathways may directly influence how some cancers grow or spread, though researchers say more studies are needed to understand the mechanism behind this effect. (iStock)
Other factors, such as participants’ health conditions, weight loss and metabolic improvements, may have influenced the results, researchers noted.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
For some specific cancer types, there may not have been enough patients represented to detect statistically significant differences.
Further randomized clinical trials are needed to evaluate these preliminary findings and to determine the specific ways in which GLP-1s control cancer progression.
NEWYou can now listen to Fox News articles!
Eliminating sugar from your diet may seem like the key to healthy eating, but research suggests it could have unintended effects on digestive health.
A study presented at ENDO 2026, the Endocrine Society’s annual meeting, suggests that a total lack of sucrose, or table sugar, may harm gut health and disrupt the body’s natural metabolism.
To explore how the total absence of dietary sugar impacts the body, researchers at the Dasman Diabetes Institute in Kuwait City conducted a 16-week study on two groups of mice. Both groups were placed on a low-fat diet, but with one critical difference.
COMMON CHEMICALS FROM FOOD ADDITIVES TO PESTICIDES MAY BE WRECKING YOUR GUT HEALTH, STUDY SAYS
One group consumed a low-fat diet that included a standard amount of sucrose, while the other group ate a low-fat diet that was completely sugar-free, according to the study’s press release.
Throughout the trial, the scientists monitored a wide variety of physiological factors, including the animals’ weight, glucose tolerance, insulin sensitivity, hormone levels, internal inflammation and the specific composition of their gut bacteria.
A total lack of dietary sugar can cause imbalances in the gut bacteria and lead to signs of fatty liver disease, even without any weight gain, researchers said. (iStock)
The study outcome suggested that completely removing sugar caused several unexpected health problems.
“Completely removing sucrose from a low-fat diet may unexpectedly disrupt gut health and promote inflammation and metabolic dysfunction,” Rasheed Ahmad, principal scientist and head of the Immunology & Microbiology Department at the Dasman Diabetes Institute, said in the release.
AMERICANS’ HIGH SUGAR CONSUMPTION PROMPTS URGENT WARNING FROM HEALTH LEADERS
Even though the mice on the sugar-free diet did not gain any extra weight compared to the control group, their internal health indicators deteriorated.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
The animals that lacked sucrose developed an imbalance in their gut microbes and increased inflammation within the intestines and liver.
They also showed signs of poor glucose regulation, insulin resistance and cellular changes associated with fatty liver disease, according to the research.
Future dietary guidelines may shift away from strict, absolute sugar bans and instead focus on overall gut health through balanced nutrition. (iStock)
“The findings suggest that complete removal of sucrose from a low-fat diet may negatively affect gut microbiota and metabolic health,” Ahmad concluded.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
While the risks of high-sugar diets are well-established, the researchers noted that little attention has been given to the effects of completely eliminating sugar from low-fat meals.
Scientists say these new findings highlight that dietary carbohydrates play a valuable role in supporting balance between the immune system and the gut microbiome.
Completely cutting sucrose from a low-fat diet can unexpectedly trigger gut inflammation and disrupt the metabolism, experts say. (iStock)
Because this research was conducted on mice over a relatively short 16-week period, further clinical trials are necessary to determine whether a completely sugar-free diet causes the same gut and liver inflammation in humans.
CLICK HERE FOR MORE HEALTH STORIES
Additionally, the study focused specifically on removing sucrose from low-fat meals, meaning the results might not apply to people eliminating sugar while following higher-fat or ketogenic eating plans, the researchers noted.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The team believes that future dietary guidelines may shift away from strict, absolute sugar restrictions and instead place a greater emphasis on maintaining a diverse, healthy population of gut bacteria through balanced nutrition.
“In the long term, these findings could help improve strategies for preventing and managing metabolic disorders, fatty liver disease and chronic inflammatory conditions,” Ahmad said.
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
NEWYou can now listen to Fox News articles!
A cure for cancer could be on the horizon in the next decade, according to experts.
During the WSJ Leadership Institute CEO Summit in London last week, Johnson & Johnson Chairman and CEO Joaquin Duato reflected on the pharmaceutical company’s projections on the future of cancer treatment.
In the next 10 years, the goal is to “try to eliminate cancer,” Duato shared.
NEW CANCER VACCINE DELIVERS STUNNING RESULT AGAINST ONE OF THE DEADLIEST SKIN CANCERS
“That’s a high goal, and we are already making significant progress in certain cancers,” he said.
Duato used multiple myeloma as an example, noting that the life expectancy is currently 10 years, when it was previously “only single years.”
Joaquin Duato, chairman and CEO of Johnson and Johnson, speaks at the Punchbowl News Conference at Union Station on March 10, 2026, in Washington, DC. (Heather Diehl/Getty Images)
“We have treatments now that utilize your own immune system to attack the cancer,” he said at the summit. “For patients who were already going into hospice, so they didn’t have any other alternative, they are [at] more than five years, with a single administration, in remission. That [is] spectacular.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“When patients see that, they cannot believe that because they have been coming to the hospital every week [for] a decade, having multiple therapies.”
The goal is to “try to eliminate cancer” in the next 10 years, the pharmaceutical executive said. (iStock)
According to Duato, Johnson & Johnson is working to understand the biology of cancer growth and to formulate new technologies to address it.
“It’s realistic to believe that we are going to cure certain cancers, and some others we’re going to turn into chronic diseases,” he predicted.
CLICK HERE FOR MORE HEALTH STORIES
“Cancer is an important thing – I cannot think about anybody who has not been touched by cancer,” he went on. “But there are many other opportunities for us to actually advance science, to address very important social problems.”
Duato called out dementia as another “important problem” in need of a solution.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
He predicted that life expectancy, which has risen steadily over the past century, will continue to increase as longevity technologies and solutions advance, improving quality of life along the way.
Duato commented that J&J has been optimistic about the role artificial intelligence will play in the future of healthcare, calling it a “force multiplier.”
Biomarkers and AI can help with the earlier diagnosis of cancer, as well as a more advanced and personalized approach to surgery, a doctor noted. (iStock)
Fox News senior medical analyst Dr. Marc Siegel agreed with Duato’s outlook on the future of cancer care, noting that certain cancers will turn into chronic diseases while others will find outright cures.
“Advances [will be] based on the use of AI to help guide targeted treatments with expanding knowledge of cancer mutations and how to target them,” he predicted, speaking to Fox News Digital.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Siegel added that biomarkers and AI can help with earlier diagnoses, as well as a more advanced and personalized approach to surgery.
J&J recently acquired Firefly Bio, a biotech firm that produces drugs that enter cancer cells to “target certain proteins that contain difficult to treat gene mutations,” the doctor added.
-
News21 minutes agoGOP Rep. Tom Kean, missing from Congress for months, set to return on June 30
-
Los Angeles, Ca2 hours agoComedian to face charges in first case from L.A. County tax fraud unit
-
Detroit, MI2 hours agoDetroit archdiocese releases last proposed parish Mass stoppages. List hits 90
-
San Francisco, CA2 hours ago
Morning Report: McKivitz Highlights Special Connection to SF 🗞️
-
Dallas, TX2 hours agoFOX’s Kasper Schmeichel compares England to Dallas Cowboys, so who are their other sports analogs?
-
Miami, FL2 hours agoMiami ‘At the Top’ for Star In-State 2028 Running Back
-
Boston, MA2 hours ago
Boston Bruins are retiring Patrice Bergeron’s No. 37 next season
-
Denver, CO3 hours agoBroncos make decision on tryout quarterback, sign 2 players
